Company intelligence / Profile preview

Celleo

Melbourne, Victoria, Australiacelleo.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Celleo has developed and delivered its first Larkem™ V40 intelligent production system to a leading CAR-T manufacturer in the United States. The company is scaling up commercial deliveries and expanding its capabilities with new state-of-the-art facilities in Melbourne. Its systems are designed to enable scalable, GMP-compliant manufacturing of advanced cell and gene therapies.

Therapeutic areas: Other
Modalities: Cell therapyGene therapy
Industry: Non-Drug Biotech

Partnerships

Collaborates with leading commercial biotherapeutics players, CDMOs, developers of novel therapeuticsLocated within Jumar Bioincubator alongside CSL, WEHI, University of Melbourne

Beyond the preview

Go deeper on Celleo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celleo.

Explore the full profile